Brind.
  1. AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.
  2. M&A activity is driving sector recovery.

AbbVie reached a definitive agreement valued at $10.9 billion with Apogee Therapeutics.

6 reports, 4 independent Updated Aug 12
Gone quiet Reached 2 outlets in its first 24 hours
Reports
6
Developments
3
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

AbbVie reached a definitive agreement valued at $10.9 billion with Apogee Therapeutics.

Who's involved

What this event is mainly about
AbbVie

How it developed

Newest first. Tap a step to see who reported it.
  1. AbbVie finalized the $10.9B acquisition of Apogee Therapeutics.1 source
  2. The acquisition of Apogee Therapeutics by AbbVie is expected to close in Q3.Sub-event
  3. AbbVie enters definitive agreement valued at $10.9 billion with Apogee Therapeutics.1 source

Keep exploring

Part of

M&A activity is driving sector recovery. All 1 developments

Within AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.

The entities involved

Coverage

Newest first; wire copies grouped